This study is for people with cancer receiving immunotherapy. The purpose of this study is to try and learn how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient will develop mild or serious side effects from the medication.
This study is for patients that have been diagnosed with multiple myeloma. The usual approach for patients with newly diagnosed multiple myeloma who are not in a study, is lenalidomide and dexamethasone in combination with bortezomib or daratumumab. This approach is approved by the Food and Drug Administration (FDA). The purpose of this study is to see if patients who have a small amount of cancer left after initial treatment (called minimal residual disease (MRD)), could benefit from adding a new drug to the usual treatment. The study approach, using a combination of four drugs, is investigational and not approved by the FDA. Patients can expect to be on this study for up to 2 years. Patients will then be followed by their doctor for up to 15 years after completion of the study or until disease progression..
This study is for patients that have been diagnosed with multiple myeloma. The study drugs are Ixazomib and lenalidomide. The purpose of this study is to compare using lenalidomide and ixazomib to using lenalidomide and placebo. Participants will be on this study until disease progression or unacceptable toxicity.
Cancer survivorship is associated with many long-term chronic health issues that arise as a result of cancer
treatment protocols. Non-pharmacological lifestyle and mind-body interventions have been shown to be
effective and critical components of a total-health strategy for cancer survivors. PranaScience Institute seeks to
develop and test a novel group video app for home-based delivery of a Yogic Breathing intervention that
reduces symptoms of cancer treatment survival and supports total-health.
This study is for subjects that have relapsed or refractory follicular lymphoma, which means your lymphoma has worsened after treatment or has not responded to treatment. This study is testing an "investigational" (not yet FDA approved drug) study drug called loncastuximab tesirine (ADCT-402). Treatment will be administered intravenously or via tablet depending on the subject's assigned treatment. The primary purpose of this study is to test whether the investigational drug called loncastuximab tesirine may be more effective treatment for relapsed or refractory follicular lymphoma than treatment with the drug idelalisib. The subject will be seen approximately once every three weeks, and may remain in the study for up to 3 years.
This study is for subjects that have been diagnosed with peripheral T-cell lymphoma (PTCL) and have received at least one prior systemic therapy for their disease. This study is testing an "investigational" (not yet FDA approved drug) study drug called Lacutamab (IPH4102). The primary purpose of this study is to evaluate the safety and effectiveness of lacutamab. The subject may remain in the study until their disease progresses or they have developed unacceptable toxicity secondary to lacutamab and can expect to be in follow-up for 1 year if they discontinue treatment in the first year.
This study is for subjects with ovarian and non-small cell lung cancer. The investigational drug used is XMT-1536 (upifitamab rilsodotin). The drug will be given intravenously "IV" during infusion.
This study will focus on two parts: dose expansion (increasing the dose used) and the pivotal cohort (safety and usefulness of UPLIFT). The purpose of the second part of the study (dose expansion) is to study further the expansion dose (increasing of the dose) of XMT-1536. The research is done based on the data from the first part of the study to ensure that it can be tolerated and is safe. The third part of this study (UPLIFT) will further study the dose recommended in the first part of the study in subjects with ovarian cancer. UPLIFT is used to determine the subjects' response rate to the study drug and the length of time the drug stays in the blood. The subjects will be in the study for 18 months.
This study is for patients who have advanced cancers, such as head and neck cancer, colorectal cancer, breast cancer, and others. This study is testing a new treatment for these types of cancer. The new test drug is called BCA101. Pembrolizumab is an approved drug by the United States Food and Drug Administration (FDA) for the diseases described in this study and will be used as approved. The type of cancer a patient has will determine whether he/she will get BCA101 alone or BCA101 in combination with pembrolizumab. Participants will receive either BCA101 alone or BCA101 in combination with pembrolizumab until the cancer gets worse, they experience bad side effects, or until they withdraw consent, or until the Investigator considers it is in his/her best interest to discontinue the study drug.
This study is for newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The purpose of this study is to find out if starting treatment with the investigational products, venetoclaz and obinutuzumab (V-O) early (before symptoms occur) affect how long you live compared to the usual approach of starting treatment after showing symptoms. Participants can expect to receive treatment for up to 12 months, until the cancer gets worse or until the side effects are too great. After study completion, participants will continue to be followed for up to 10 years.